Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky Today Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited ("Immutep Limited") (NASDAQ: IMMP) concerning potential violations of the federal securities laws.
On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and cited "strong operational progress" for the trial. The filing contained no reference to negative efficacy signals, enrollment difficulties, or data trends that might compromise the trial's primary endpoints. Six weeks later, on March 13, 2026, the IDMC announced the interim futility analysis showed the drug was unlikely to succeed and recommended stopping the study. TACTI-004 was Immutep's lead oncology asset.
The January 30 filing framed the futility analysis as a forward milestone still approaching. The March 13 announcement revealed the analysis had concluded -- and the result was negative. The gap between the guidance and the outcome drove shares down as much as 90% in a single session.
If you suffered a loss on your Immutep Limited securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290420
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky Today
2026-03-30 12:14 AM EDT
Did Aldeyra Therapeutics, Inc. (ALDX) Mislead Investors? Levi & Korsinsky Investigates
2026-03-30 12:12 AM EDT
Levi & Korsinsky Launches Fraud Investigation on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders
2026-03-30 12:10 AM EDT
May 29, 2025
When your company’s earnings news hits the market, stock prices can react in milliseconds. A 2025 UC San Diego study analyzing over 89...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services